Ezetimibe is approved by FDA drug. Primary it is designed to lower blood cholesterol levels by inhibiting the Niemann–Pick C1-Like 1 (NPC1L1) protein, its reducing cholesterol absorption in the intestine. Drugs mechanism lowers cholesterol levels and also decreases the risk of cardiovascular events. In recent studies was uncovered Ezetimibe's potential in cancer therapy showcasing its versatile applications in both lipid management and oncology.
Yin, Y., Wu, C., Zhou, Y., Zhang, M., Mai, S., Chen, M., and Wang, H.-Y. (2024) Ezetimibe induces paraptosis through Niemann–Pick C1-like 1 inhibition of mammalian-target-of-rapamycin signaling in hepatocellular carcinoma cells. Genes.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For more details consult with your doctor or healthcare professional.
Yin, Y., Wu, C., Zhou, Y., Zhang, M., Mai, S., Chen, M., and Wang, H.-Y. (2024) Ezetimibe induces paraptosis through Niemann–Pick C1-like 1 inhibition of mammalian-target-of-rapamycin signaling in hepatocellular carcinoma cells. Genes.
Yin, Y., Wu, C., Zhou, Y., Zhang, M., Mai, S., Chen, M., and Wang, H.-Y. (2024) Ezetimibe induces paraptosis through Niemann–Pick C1-like 1 inhibition of mammalian-target-of-rapamycin signaling in hepatocellular carcinoma cells. Genes.
Yin, Y., Wu, C., Zhou, Y., Zhang, M., Mai, S., Chen, M., and Wang, H.-Y. (2024) Ezetimibe induces paraptosis through Niemann–Pick C1-like 1 inhibition of mammalian-target-of-rapamycin signaling in hepatocellular carcinoma cells. Genes.
Home
